Portal DiabetesTM
Portal PumpTM
The Artificial Pancreas
A revolutionary solution – fully automated, implantable insulin delivery
  • Portal Diabetes, Inc.™ is developing the Portal Pump™: the first artificial pancreas
  • No more carb counting, no more meal announcements, no more sleep interruption
  • Superior outcomes, superior experience
The products described on this website are in the research and development stage. They are not approved by the U.S. Food and Drug Administration and are not available for clinical use or sale in any country.
Why Portal DiabetesTM?

Only 20% of adults living with type 1 diabetes (T1D) achieve glycemic targets according to the American Diabetes Association.

The management burden adds up to about 2,000 annual tasks when things go right. The Portal Pump will only involve 5 to 40 tasks annually.
Portal is developing the first artificial pancreas to functionally cure type 1 diabetes, delivering exceptional health outcomes and reducing management burden.
Availability of Therapies for Type 1 Diabetes by the Years
About us
Portal DiabetesTM: developing the first artificial pancreas
Portal is developing the first artificial pancreas, a fully automated insulin delivery system, made possible by the fast pharmacokinetics of insulin delivered to the intraperitoneal space, an implantable pump, heat stable insulin, and modern continuous glucose monitor (CGM) technology. The Portal PumpTM is anticipated to deliver an average time in range of about 90 percent while relieving patients of the relentless management burden. Patients will no longer need to provide carbohydrate counts, meal announcements, exercise announcements, or wake in the night to manage their blood glucose. By restoring the function of a pancreas, Portal Pump TM empowers patients to effortlessly achieve excellent health outcomes.
Our Team
The Portal DiabetesTM team is comprised of talented and experienced people devoted to the mission of bringing the first artificial pancreas to patients living with type 1 diabetes.
Stacy Chambliss
Chief Executive Officer
Lee Hartley
Chief Technology Officer
Ted Randolph
Chief Operations Officer
Austin Smith
Head of Engineering
Nico Varas
Head of Drug Development
Juan Gonzalez
Head of Manufacturing
The Challenge
Diabetes | The Elusive Balancing Act
Patients are overwhelmed
  • 24/7 titration with subcutaneous insulin is required with unpredictable outcomes.
  • Skin site management; infections, tape allergies
  • Pump maintenance
  • Refrigeration of insulin
  • Purchasing insulin and disposable supplies
  • Frequent insurance interaction
Today’s tools are nontargeted and deficient.
  • Multiple daily injection and pump therapy rely upon subcutaneous delivery of insulin
  • Insulin must travel the body for absorption in the blood stream
  • Connective tissue is a physiologic barrier to insulin delivery after subcutaneous administration
  • The Portal Pump delivers insulin to the peritoneal space where the liver soon receives it
CURRENT THERAPY DOES NOT DELIVER INSULIN TO THE NORMAL PHYSIOLOGIC SITE.
‍
It’s time for a new approach!
Technology
The Technology
SOLUTION | Portal Pump™
An implantable pump delivers insulin to the right space
Just as it would for a normal pancreas, insulin is delivered directly to the liver.
Rapid uptake of intraperitoneal insulin enables a basic control algorithm to fully automate insulin delivery.
The device is refilled with insulin after weeks or months of therapy. Like a pacemaker or pain pump, the Portal PumpTM is implanted during an outpatient procedure, where it remains for 5-7 years until replaced.
Contact
Copyright © 2025